BIS vs. SSO

Last updated Jun 24, 2026

BIS (ProShares UltraShort Nasdaq Biotechnology) and SSO (ProShares Ultra S&P500) are both Leveraged Equities funds from ProShares - BIS tracks the NASDAQ Biotechnology Index (-200%) while SSO tracks the S&P 500. Both are passively managed. Over the past 10 years, BIS returned -26.06%/yr vs 24.26%/yr for SSO. At a correlation of -0.61, they often move in opposite directions. BIS charges 0.95%/yr vs 0.87%/yr for SSO.

Performance

BIS vs. SSO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares UltraShort Nasdaq Biotechnology (BIS) and ProShares Ultra S&P500 (SSO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BIS achieves a -17.93% return, which is significantly lower than SSO's 12.95% return. Over the past 10 years, BIS has underperformed SSO with an annualized return of -26.06%, while SSO has yielded a comparatively higher 24.26% annualized return.

BIS

• 1D: -1.74%
• 1M: -10.00%
• YTD: -17.93%
• 6M: -14.94%
• 1Y: -55.93%
• 3Y*: -24.98%
• 5Y*: -14.70%
• 10Y*: -26.06%

SSO

• 1D: -2.86%
• 1M: -3.30%
• YTD: 12.95%
• 6M: 10.86%
• 1Y: 42.28%
• 3Y*: 33.83%
• 5Y*: 17.91%
• 10Y*: 24.26%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BIS vs. SSO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BIS ProShares UltraShort Nasdaq Biotechnology	-17.93%	-45.95%	4.79%	-6.54%	-2.14%	-14.74%	-56.01%	-41.01%	5.14%	-36.98%
SSO ProShares Ultra S&P500	12.95%	26.19%	43.48%	46.65%	-38.98%	60.57%	21.54%	63.45%	-14.60%	44.35%

Correlation

The correlation between BIS and SSO is -0.48, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.48
Correlation (3Y) Calculated over the trailing 3-year period	-0.54
Correlation (5Y) Calculated over the trailing 5-year period	-0.58
Correlation (10Y) Calculated over the trailing 10-year period	-0.60
Correlation (All Time) Calculated using the full available price history since Apr 8, 2010	-0.61

The correlation between BIS and SSO shifts across timeframes, from -0.61 (all time) to -0.48 (1 year), reflecting how their relationship changes across market environments.

Return for Risk

BIS vs. SSO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIS

BIS Risk / Return Rank: 0
BIS Sharpe Ratio Rank: 0
BIS Sortino Ratio Rank: 0
BIS Omega Ratio Rank: 0
BIS Calmar Ratio Rank: 0
BIS Martin Ratio Rank: 2

SSO

SSO Risk / Return Rank: 50
SSO Sharpe Ratio Rank: 51
SSO Sortino Ratio Rank: 46
SSO Omega Ratio Rank: 48
SSO Calmar Ratio Rank: 49
SSO Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIS vs. SSO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares UltraShort Nasdaq Biotechnology (BIS) and ProShares Ultra S&P500 (SSO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BIS	SSO	Difference
Sharpe ratio: Return per unit of total volatility	-1.38	1.71	-3.09
Sortino ratio: Return per unit of downside risk	-2.34	2.24	-4.58
Omega ratio: Gain probability vs. loss probability	0.75	1.30	-0.55
Calmar ratio: Return relative to maximum drawdown	-1.02	2.34	-3.36
Martin ratio: Return relative to average drawdown	-1.39	9.90	-11.29

BIS vs. SSO - Sharpe Ratio Comparison

The current BIS Sharpe Ratio is -1.38, which is lower than the SSO Sharpe Ratio of 1.71. The chart below compares the historical Sharpe Ratios of BIS and SSO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BIS vs. SSO - Drawdown Comparison

The maximum BIS drawdown since its inception was -99.87%, which is greater than SSO's maximum drawdown of -84.67%. Use the drawdown chart below to compare losses from any high point for BIS and SSO.

Drawdown Indicators

	BIS	SSO	Difference
Max Drawdown Largest peak-to-trough decline	-99.87%	-84.67%	-15.20%
Max Drawdown (1Y) Largest decline over 1 year	-55.07%	-18.17%	-36.90%
Max Drawdown (3Y) Largest decline over 3 years	-67.92%	-35.21%	-32.71%
Max Drawdown (5Y) Largest decline over 5 years	-75.59%	-46.73%	-28.86%
Max Drawdown (10Y) Largest decline over 10 years	-95.40%	-59.34%	-36.06%
Current Drawdown Current decline from peak	-99.87%	-6.70%	-93.17%
Average Drawdown Average peak-to-trough decline	-90.04%	-19.53%	-70.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	41.32%	4.28%	+37.04%

Volatility

BIS vs. SSO - Volatility Comparison

ProShares UltraShort Nasdaq Biotechnology (BIS) has a higher volatility of 13.79% compared to ProShares Ultra S&P500 (SSO) at 9.70%. This indicates that BIS's price experiences larger fluctuations and is considered to be riskier than SSO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BIS	SSO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.79%	9.70%	+4.09%
Volatility (6M) Calculated over the trailing 6-month period	32.10%	19.65%	+12.45%
Volatility (1Y) Calculated over the trailing 1-year period	40.51%	24.92%	+15.59%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.80%	33.85%	+9.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	46.26%	35.93%	+10.33%

BIS vs. SSO - Expense Ratio Comparison

BIS has a 0.95% expense ratio, which is higher than SSO's 0.87% expense ratio.

Dividends

BIS vs. SSO - Dividend Comparison

BIS's dividend yield for the trailing twelve months is around 5.61%, more than SSO's 0.65% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BIS ProShares UltraShort Nasdaq Biotechnology	5.61%	5.25%	3.73%	1.75%	0.00%	0.00%	0.45%	2.11%	0.37%	0.00%	0.00%	0.00%
SSO ProShares Ultra S&P500	0.65%	0.68%	0.85%	0.18%	0.50%	0.18%	0.20%	0.50%	0.75%	0.39%	0.51%	0.63%

Frequently Asked Questions

Can I hold both BIS and SSO in my portfolio?

BIS and SSO have a correlation of -0.48, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BIS or SSO?

BIS has higher volatility (13.79%) compared to SSO (9.70%). In terms of maximum drawdown, BIS dropped -99.87% vs SSO's -84.67%.

Which ETF is better, BIS or SSO?

On 10-year performance, SSO leads with 24.26% vs -26.06% for BIS. On fees, SSO is cheaper at 0.87% per year. On volatility, SSO has been the lower-risk option at 9.70%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, BIS or SSO?

Over the 10-year period, SSO has performed better with a 24.26% return vs -26.06%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, BIS or SSO?

SSO is cheaper with a 0.87% expense ratio, compared with 0.95% for BIS.

Which ETF pays a higher dividend yield, BIS or SSO?

BIS has the higher dividend yield at 5.61%, compared with 0.65% for SSO.

What is the main difference between BIS and SSO?

BIS tracks NASDAQ Biotechnology Index (-200%), while SSO tracks S&P 500. Their fees differ too: 0.95% for BIS and 0.87% for SSO.

Which has better risk-adjusted returns?

SSO currently has the higher Sharpe Ratio (1.71 vs -1.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.